Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab in Advanced Chemotherapy Resistant CRC with MSI-like Signature
NCT02982694Phase 2Terminated
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Nov 2017
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in colorectal cancer (CRC), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Overall Response Rate at 36 months. Started Nov 2017; status: terminated.
02
Drugs
atezolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02982694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982694.